<DOC>
	<DOCNO>NCT02809573</DOCNO>
	<brief_summary>The purpose dose-escalation study assess safety tolerability treatment Chidamide range dos combine CHOP fix dose patient newly diagnose peripheral T-cell lymphoma .</brief_summary>
	<brief_title>Clinical Trial Chidamide Combined With CHOP Peripheral T-cell Lymphoma Patients</brief_title>
	<detailed_description>The purpose study assess tolerability safety include adverse event , vital sign , laboratory test , etc. , range dos chidamide combine CHOP peripheral T-cell lymphoma patient , determine dose limit toxicity maximum tolerable dose .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Male female age 1865 year old ; 2 . Histopathologically confirm Peripheral T cell Lymphoma ( PTCL ) include : PTCLunspecified ; Angioimmunoblastic Tcell lymphoma ; Anaplastic large cell lymphoma , ALK positive negative ; Subcutaneous panniculitis Tcell lymphoma ; Cutaneous / Tcell lymphoma ; Other Tcell lymphoma investigator consider appropriate enrol ; 3 . Patients receive antitumor therapy ; 4 . In Ann Arbor disease stage ; 5 . ECOG performance status 01 ; 6 . Patients without bone marrow involvement . The absolute number neutrophile less 2.0 * 10^9/L , platelet le 100 * 10^9/L . And concentration hemoglobin le 110 g/L ; 7 . Life expectancy le 6 month ; 8 . Patients sign Informed Consent Form . 1 . Patients central nervous system meninges involvement ; 2 . Patients treat radiotherapy , chemotherapy immunotherapy PTCL ; 3 . Patients uncontrollable significant cardiovascular disease include : history myocardial infarction ; uncontrollable angina within 6 month screen , take antiangina drug time screening ; history congestive heart failure , leave ventricular ejection fraction ( LVEF ) &lt; 50 % time screening ; clinically significant ventricular arrhythmia ventricular tachycardia , ventricular fibrillation torsades de pointes ; History supraventricular arrhythmia nodal arrhythmia could control drug need pacemaker ; History cardiomyopathy ; History clinically significant QTc interval prolongation , QTc interval &gt; 450 m screening ; Coronary disease symptom need drug therapy ; 4 . Patients undergone organ transplantation ; 5 . Patients thromboembolic disease , hematencephalon cerebral infraction within 4 week screen , patient anticoagulant therapy ; 6 . Patients clinically significant abnormality gastrointestinal tract , dysphagia , chronic diarrhea intestinal obstruction may affect uptake , transformation absorption drug ; 7 . Patients active infection , include active bacterial , viral , fungoid , mycobacterium , parasite infection ( include hyponychium fungoid infection ) , infection need treat intravenous antibody therapy , antiviral therapy , serious infection need treat hospitalization ; 8 . Patients conduct surgery major organ le 6 week ; 9 . Hepatic function : Serum total bilirubin &gt; 1.5 fold normal range ; ALT/AST &gt; 2.5 fold normal range 5 fold liver metastasis ; Renal function : Serum creatine &gt; 1.5 fold normal range ; 10 . Patients malignancy past ( except basal cell carcinoma , squamouscell carcinoma carcinoma situs cervix adequately treat ) , unless malignancy radically treat evidence recurrence 5 year ; 11 . Pregnant lactating woman patient childbearing age carry birth control ; 12 . Patients mental disorder , may affect understand execution inform consent compliance study ; 13 . Drug abuse long term alcoholism could affect evaluation study result ; 14 . Patients consider investigator suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>PTCL</keyword>
	<keyword>chidamide</keyword>
	<keyword>CHOP</keyword>
	<keyword>phase Ib</keyword>
</DOC>